|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL
Departments of Medicine (T.S., P.H., M.C.M.) and Urology (T.S.), University of Essen, Essen, Germany; and Department of Pharmacology and Pharmacotherapy, University of Amsterdam, Amsterdam, The Netherlands (M.C.M.)
We have reexamined the muscarinic receptor subtype mediating carbachol-induced contraction of rat urinary bladder and investigated the role of phospholipase (PL)C, D, and A2 and of intra- and extracellular Ca2+ sources in this effect. Based on the nonsubtype-selective tolterodine, the highly M2 receptor-selective (R)-4-{2-[3-(4-methoxy-benzoylamino)-benzyl]-piperidin-1-ylmethyl}-piperidine-1-carboxylic acid amide (Ro-320-6206), and the highly M3 receptor-selective darifenacin and 3-(1-carbamoyl-1,1-diphenylmethyl)-1-(4-methoxyphenylethyl)pyrrolidine (APP), contraction occurs via M3 receptors. Carbachol stimulated inositol phosphate formation in rat bladder slices, and this was abolished by the phospholipase C inhibitor 1-(6-[([17
]-3-methoxyestra-1,3,5[10]-trien-17-yl)-amino]hexyl)-1H-pyrrole-2,5-dione (U 73,122; 10 µM). Nevertheless, U 73,122 (110 µM) did not significantly affect carbachol-stimulated bladder contraction. Carbachol had only little effect on PLD activity in bladder slices, but the PLD inhibitor butan-1-ol, relative to its negative control butan-2-ol (0.3% each), caused detectable inhibition of carbachol-induced bladder contraction. The cytosolic PLA2 inhibitor arachidonyltrifluoromethyl ketone weakly inhibited carbachol-induced contraction at a concentration of 300 µM, but the cyclooxygenase inhibitor indomethacin (110 µM) remained without effect. The Ca2+ entry blocker nifedipine (10100 nM) almost completely inhibited carbachol-induced bladder contraction. In contrast, 1-[
-[3-(4-methoxyphenyl)propoxy]-4-methoxyphenethyl]-1H-imidazole HCl (SKF 96,365; 10 µM), an inhibitor of store-operated Ca2+ channels, caused little inhibition. We conclude that carbachol-induced contraction of rat bladder largely depends on Ca2+ entry through nifedipine-sensitive channels and, perhaps, PLD, PLA2, and store-operated Ca2+ channels, whereas cyclooxygenase and, surprisingly, also PLC are not involved to a relevant extent.
Address correspondence to: Professor Martin C. Michel, Academisch Medisch Centrum, Afd. Farmacologie en Farmacotherapie, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands. E-mail: m.c.michel{at}amc.uva.nl
This article has been cited by other articles:
![]() |
M. Basha, E. F. LaBelle, G. M. Northington, T. Wang, A. J. Wein, and S. Chacko Functional significance of muscarinic receptor expression within the proximal and distal rat vagina Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2009; 297(5): R1486 - R1493. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-L. Zhu, K. L. Brain, M. Aishima, A. Shibata, J. S. Young, K. Sueishi, and N. Teramoto Actions of Two Main Metabolites of Propiverine (M-1 and M-2) on Voltage-Dependent L-Type Ca2+ Currents and Ca2+ Transients in Murine Urinary Bladder Myocytes J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 118 - 127. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. P. Frazier, A. S. Braverman, S. L. M. Peters, M. C. Michel, and M. R. Ruggieri Sr. Does Phospholipase C Mediate Muscarinic Receptor-Induced Rat Urinary Bladder Contraction? J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 998 - 1002. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Benitez-Rajal, M.-J. Lorite, A. D. Burt, C. P. Day, and M. G. Thompson Phospholipase D and extracellular signal-regulated kinase in hepatic stellate cells: effects of platelet-derived growth factor and extracellular nucleotides. Am J Physiol Gastrointest Liver Physiol, November 1, 2006; 291(5): G977 - G986. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Braverman, A. S. Tibb, and M. R. Ruggieri Sr M2 and M3 Muscarinic Receptor Activation of Urinary Bladder Contractile Signal Transduction. I. Normal Rat Bladder J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 869 - 874. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. P. Frazier, M.-J. Mathy, S. L. M. Peters, and M. C. Michel Does Cyclic AMP Mediate Rat Urinary Bladder Relaxation by Isoproterenol? J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 260 - 267. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-E. Andersson and A. J. Wein Pharmacology of the Lower Urinary Tract: Basis for Current and Future Treatments of Urinary Incontinence Pharmacol. Rev., December 1, 2004; 56(4): 581 - 631. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Schneider, C. Fetscher, S. Krege, and M. C. Michel Signal Transduction Underlying Carbachol-Induced Contraction of Human Urinary Bladder J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1148 - 1153. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Fleichman, T. Schneider, C. Fetscher, and M. C. Michel Signal Transduction Underlying Carbachol-Induced Contraction of Rat Urinary Bladder. II. Protein Kinases J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 54 - 58. [Abstract] [Full Text] [PDF] |
||||